key: cord-0691161-p0wkhzw1 authors: Armstrong, R. A.; Kane, A. D.; Kursumovic, E.; Oglesby, F. C.; Cook, T. M. title: Mortality in patients admitted to intensive care with COVID‐19: an updated systematic review and meta‐analysis of observational studies date: 2021-02-01 journal: Anaesthesia DOI: 10.1111/anae.15425 sha: 842444f580a63fd58b3369007df177e762a1728d doc_id: 691161 cord_uid: p0wkhzw1 The COVID‐19 pandemic continues to cause critical illness and deaths internationally. Up to 31 May 2020, mortality in patients admitted to intensive care units (ICU) with COVID‐19 was 41.6%. Since then, changes in therapeutics and management may have improved outcomes. Also, data from countries affected later in the pandemic are now available. We searched MEDLINE, Embase, PubMed and Cochrane databases up to 30 September 2020 for studies reporting ICU mortality among adult patients with COVID‐19 and present an updated systematic review and meta‐analysis. The primary outcome measure was death in intensive care as a proportion of completed ICU admissions, either through discharge from intensive care or death. We identified 52 observational studies including 43,128 patients, and first reports from the Middle East, South Asia and Australasia, as well as four national or regional registries. Reported mortality was lower in registries compared with other reports. In two regions, mortality differed significantly from all others, being higher in the Middle East and lower in a single registry study from Australasia. Although ICU mortality (95%CI) was lower than reported in June (35.5% (31.3–39.9%) vs. 41.6% (34.0–49.7%)), the absence of patient‐level data prevents a definitive evaluation. A lack of standardisation of reporting prevents comparison of cohorts in terms of underlying risk, severity of illness or outcomes. We found that the decrease in ICU mortality from COVID‐19 has reduced or plateaued since May 2020 and note the possibility of some geographical variation. More standardisation in reporting would improve the ability to compare outcomes from different reports. The global COVID-19 pandemic continues to impact international health and healthcare delivery [1] . To date, the World Health Organization has recorded more than 96 million cases worldwide, with the real number likely many-fold higher, and more than 2 million confirmed deaths [2] . Intensive care units (ICU) have an important role in managing the sickest of these patients, but mortality is high in this group. We conducted an initial systematic review and meta-analysis of 24 observational studies published by 31 May 2020, which included 10,150 patients, finding that mortality was 41.6%, with evidence that this was decreasing as the pandemic progressed [3, 4] . In the last few months, several studies have clarified which treatments do and do not provide benefit in the ICU management of COVID-19. Steroids (particularly dexamethasone) were shown in early June to improve survival in patients who are oxygen-dependent or receiving mechanical respiratory support [5, 6] , while other drugs including chloroquine, azithromycin, lopinavir/ritonavir and remdesivir have been shown to have no clear mortality benefit [7] [8] [9] . Management of COVID-19 has also likely evolved over the year with changes in approaches to oxygen therapy, fluids and anticoagulation management [10, 11] . Since our first meta-analysis, the pandemic has spread further into the southern hemisphere and there has been time for studies from more countries to be reported. Given these developments, mortality from COVID-19 in patients admitted to the ICU may have altered further. Here, we update the previous systematic review and meta-analysis to include studies published up to 30 September 2020. The review, including our intention to update the analyses and outputs as new data came to light, was prospectively registered with PROSPERO and conducted according to preferred reporting items for systematic reviews and metaanalyses (PRISMA) guidelines [12] . The search strategy up to 31 May 2020 has been previously described [3] . We repeated the search of MEDLINE, Embase, PubMed and the Cochrane Library up until 30 September 2020 using the search terms "coronavirus", "covid19", "sars-cov-2" or "2019-ncov"; and "intensive care", "mortality" or "disease course". The exact terms used were adapted to each database (online Supporting Information, Table S1 ). Manual searching was used to identify additional results. We also contacted intensive care registries run by national societies (online Supporting Information, [13] as used in other analyses [14] , but included Australia and New Zealand (Australasia) as an independent region from others in the East Asia and Pacific grouping as they are geopolitically discrete and experienced a later first surge. Microsoft Excel (Microsoft, Inc., Redmond, CA, USA). All articles were screened independently by two authors (two of RA, AK, EK, FO) to identify studies potentially meeting inclusion criteria. The full texts of potentially eligible studies were independently assessed for eligibility with disagreements resolved by discussion with a third reviewer (TC). The pre-specified primary outcome was the mortality rate in patients with completed ICU admission. Data were only included when this outcome was reported clearly. Other pre-defined data items extracted included study setting and design, including information for risk of bias assessment, patient characteristics, clinical features and rates of organ support delivered. We used a modified version of the Newcastle-Ottawa Scale (online Supporting Information, Table S3 ) to assess the quality of included studies, as previously described, and funnel plot asymmetry to assess heterogeneity and risk of publication bias [3, 15] . Meta-analysis was conducted using the 'meta' package (Version 4.15-1, 2020) in R (The R Foundation for Statistical Computing; Version 4.0.3, 2020). An inverse-variance random-effects model was used for all analyses. Betweenstudy heterogeneity was assessed using the I 2 test. A funnel plot was produced using the Public Health England tool [15] . To further explore heterogeneity, we performed subgroup analyses based on study methodology (single-or multi-centre; number of participants; censoring of ICU outcomes) and geographical location (both region and World Bank income region [13] ). We also conducted a sensitivity analysis excluding all national registries. Metaregression was used to explore the effects of patient characteristics and treatments (proportion ventilated; average age; proportion of male sex); geographical location; publication date; and proportion of patients with outcomes reported. The updated search found an additional 7341 articles available since our previous analysis [3] , including 1359 duplicates, leaving 5982 to be screened. After exclusion by title or abstract of 5787 articles, 195 full-text articles were reviewed, of which 28 reported the primary outcome of interest. One of these was an updated report from Lombardy [16] . Three studies from Wuhan, China were excluded to avoid data duplication due to the overlap of both the data collection period and hospital location [17] [18] [19] . A report from the European Risk Stratification in COVID-19 patients in the ICU (RISC-19-ICU) cohort was included as it was not possible to determine whether patients were duplicated in other series [20] . Manual searching and direct contact yielded five additional regional or national registries, including an updated report from the UK's Intensive Care National Audit and Research Centre (ICNARC). To avoid duplication of cases, two earlier reports from the Netherlands [21, 22] and one from Germany [23] were excluded. A total of 52 reports were included in the analysis [16, 20, Denmark (n = 2) [39, 65] ; Australia [71] ; Belgium [69] ; Europe [20] ; Germany [72] ; Greece [55] ; Hong Kong [31] ; Iceland [59] ; India [50] ; Iran [49] ; Israel [56] ; Italy [16] ; Kuwait [51] ; Netherlands [73] ; Poland [68] ; Scotland [52] ; Singapore [26] ; Sweden [64] ; UK [70]; and Yemen [67] (n = 1 each). Reported ICU mortality rates ranged from 0% to 84.6%, with values at both extremes arising from small case series. Table S4 ). Details of ICU treatments were variably reported making further analysis of the impact of treatment on the outcome, other than invasive mechanical ventilation, impractical (online Supporting Information, Table S5 ). The ICU mortality rate (95%CI) across all studies included in the quantitative analysis was 35.5% (31.3-39.9%), I 2 = 97.6% (Fig. 3) . The largest patient cohorts were from national registries of Germany (19, 229 patients [72] ) and the UK (11,480 [70] ). A sensitivity analysis removing all national and regional registries [52, [70] [71] [72] [73] did not significantly affect the mortality rate or heterogeneity (36.8% (31.6-42.4%), I 2 = 91.8%) and Egger's test of funnel plot asymmetry was negative (t = 0.89, p = 0.38; Fig. 4 ). In a sub-group analysis, the mortality reported in the registries was significantly lower than in other reports [71] , with similar rates elsewhere (between-group differences p < 0.001). Mortality was higher in the one low-income country [67] but similar in other income groups (between-group differences p < 0.001). Subgroup analysis by month of publication demonstrated higher mortality in the earliest reported series (betweengroup differences p < 0.05) ( Table 2) . Sub-group analyses based on study characteristics (single or multiple centres; sample size; complete outcome reporting) showed no significant between-group differences or substantial reductions in heterogeneity (online Supporting Information, Table S6 ). Multivariate meta-regressions based on patient characteristics and treatments (age; male sex; proportion of invasively ventilated patients) and proportion of patient outcomes reported (i.e. the proportion of patients in each study with a completed ICU stay) were not significant. Sweden; Switzerland; Yemen) and several national and regional registries which had reported outcomes in the intervening months. and publication has progressively increased (Fig. 2) . Additionally, this single time-point is only a proxy for the timeline of admissions in each study, which cannot be evaluated further due to a lack of patient-level data. Metaregression also did not show clear temporal improvements within individual regions, when adjusted for other variables. Thus, the clear fall in mortality over time observed between January and May is now less evident, and while over time mortality has undoubtedly fallen, it is likely that the improvement has reduced or plateaued. We are not able to comment on whether mortality has reduced at specific time points, such as since the randomised evaluation of COVID-19 therapy (RECOVERY) study reported reduced mortality with the use of dexamethasone [5] , as this would likely require individual patient-level data and separation of cohorts into those admitted before and after the relevant time-point, which is not currently available. In most geographical regions, the mortality rate is 30- increased the demand on ICU in those locations and will merit further analysis in due course. To counter this, vaccination is now available in many countries and we can hope that this too will, over several months, positively impact on the pandemic trajectory and demand on ICU care. In conclusion, this expanded meta-analysis of survival of patients admitted to ICU with COVID-19 has shown that any fall in mortality rate between June and September appears to have flattened or plateaued. We have identified geographical regions of both low (Australasia) and high (Middle East) mortality that merit further exploration. Mortality rate is lower in reports from registries than from non-registry studies. Further analysis is hampered by a lack of definitions and standardisation of reporting. Standardisation of reporting would enable far more valuable comparisons of outcomes between locations and over time. Registries may be the best-placed organisations to act on this first. Despite these limitations, this analysis provides an overview of outcomes among patients admitted to ICU with COVID-19 in the first pandemic surge. Additional supporting information may be found online via the journal website. Figure S1 . Proportion of included patients with outcome reported (red) and not reported (blue) for each study, grouped by geographical region. Table S1 . Search strategy. Table S2 . Registries or societies contacted directly. Table S3 . Modified Newcastle-Ottawa Scale. Table S4 . Study quality and risk of bias assessment. Table S5 . Reported clinical features, rates of organ support and pharmacotherapy. Table S6 . Sensitivity and sub-group analyses. Table S7 . Results of meta-regression analyses. World Health Organization. Coronavirus disease (COVID-19) Pandemic World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard Outcomes from intensive care in patients with COVID-19: a systematic review and metaanalysis of observational studies Decreasing mortality rates in ICU during the COVID-19 pandemic Dexamethasone in hospitalized patients with Covid-19 -Preliminary Report Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis Efficacy of remdesivir in COVID-19 Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial COVID-19 and its implications for thrombosis and anticoagulation The Faculty of Intensive Care Medicine and The Intensive Care Society. Clinical guide for the management of critical care for adults with COVID-19 during the Coronavirus pandemic Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement World Bank Country and Lending Groups International Severe Acute Respiratory and Emerging Infection Consortium. COVID-19 Evidence & Reports Funnel plot tool for proportions Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort Incidence of thrombotic complications in critically ill ICU patients with COVID-19 COVID-19 in critically ill patients in North Brabant, the Netherlands: patient characteristics and outcomes Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China Covid-19 in critically ill patients in the Seattle region -case series Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study Clinical course and outcomes of 344 intensive care patients with COVID-19 SARS-Cov-2 in Spanish intensive care: early experience with 15-day survival in Vitoria Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study Clinical and autoimmune characteristics of severe and critical cases with COVID-19 High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Initial experiences from patients with COVID-19 on ventilatory support in Denmark Characteristics and outcomes of coronavirus disease patients under nonsurge conditions Venous thromboembolism in critically ill patients with Covid-19: results of a screening study for deep vein thrombosis Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou ICU and ventilator mortality among critically ill adults with coronavirus disease 2019 Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019 Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study A cohort of patients with COVID-19 in a major teaching hospital in Europe Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019 Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran Initial experience of critically ill patients with COVID-19 in Western India: a case series Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait Scottish Intensive Care Society Audit Group report on COVID-19 Epidemiological characteristics of the COVID-19 outbreak in a secondary hospital in Spain Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area-a retrospective cohort study Demographic and clinical features of critically ill patients with COVID-19 in Greece: the burden of diabetes and obesity Clinical course and outcomes of severe Covid-19: a national scale study Preparedness and reorganization of care for coronavirus disease 2019 patients in a Swiss ICU: characteristics and outcomes of 129 patients The first 100 cases of COVID-19 in a hospital in Madrid with a 2-month follow-up Nationwide incidence and outcomes of patients with coronavirus disease 2019 requiring intensive care in Iceland Clinical experience with COVID-19 at a specialty orthopedic hospital converted to a pandemic overflow field hospital Clinical outcomes in critically ill coronavirus disease 2019 patients: a unique New York City public hospital experience Epidemiological and clinical features of 201 COVID-19 patients in Changsha Respiratory support in severely or critically ill ICU patients with COVID-19 in Wuhan Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary hospital in Characteristics, interventions, and longer term outcomes of COVID-19 ICU patients in Denmark -a nationwide, observational study Early experience with critically ill patients with COVID-19 in Montreal Critical care for COVID-19 during a humanitarian crisis -lessons learnt from Yemen Intensive care unit admissions during the first 3 months of the COVID-19 pandemic in Poland: a Single-Center, Cross-Sectional Study Intensive care unit acquired muscle weakness in COVID-19 patients Intensive Care National Audit and Research Centre I. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland Australian and New Zealand Intensive Care Society (ANZICS) COVID-19) daily situation report of the Robert Koch Institute COVID-19 in Dutch intensive care units; patient characteristics and outcomes compared with pneumonia patients in the ICU from Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region Intensive Care National Audit and Research Centre. ICNARC report on COVID-19 in critical care -29th Trends in intensive care for patients with COVID-19 in England, Wales and Northern Ireland This study was prospectively registered with PROSPERO